Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06215859Phase 3Completed

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Role: lead

NCT06215820Phase 3Completed

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Role: lead

NCT04570436Phase 4Completed

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

Role: lead

NCT05053126Phase 4Completed

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

Role: lead

NCT05319756Phase 4Completed

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

Role: lead

All 5 trials loaded